Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 10/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.44 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5117313 | 0.90 | KDM4E (0.46) | TAS2R14ALDH1A1 | |
| SCHEMBL5117317 | 0.90 | KDM4E (0.46) | TAS2R14ALDH1A1 | |
| SCHEMBL5623622 | 0.89 | TAS2R14 (0.57) | TAS2R14MEN1KMT2APSEN1PSEN2 | |
| SCHEMBL5117430 | 0.88 | TAS2R14 (0.62) | TAS2R14MEN1KMT2APSEN1PSEN2 | |
| SCHEMBL5117441 | 0.88 | TAS2R14 (0.62) | TAS2R14MEN1KMT2APSEN1PSEN2 | |
| SCHEMBL5122055 | 0.80 | KDM4E (0.53) | TAS2R14PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5122060 | 0.80 | KDM4E (0.53) | TAS2R14PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5113920 | 0.79 | KDM4E (0.45) | TAS2R14ALDH1A1 | |
| SCHEMBL5119869 | 0.79 | PSEN1 (0.46) | TAS2R14PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5119864 | 0.79 | PSEN1 (0.46) | TAS2R14PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7345095-B2 | Sulfonamide compounds for the treatment of neurodegenerative disorders | PFIZER INC (US) | 2008-03-18 | — | — | US | disclosed |
| US-20070129349-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER INC | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129349-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PSEN1, APP, PSEN2 | TAS2R14 1345/4885LMNA 1925/4885MEN1 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.